These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 32422235)

  • 21. GFI1B and LSD1 repress myeloid traits during megakaryocyte differentiation.
    Venhuizen J; van Bergen MGJM; Bergevoet SM; Gilissen D; Spruijt CG; Wingens L; van den Akker E; Vermeulen M; Jansen JH; Martens JHA; van der Reijden BA
    Commun Biol; 2024 Mar; 7(1):374. PubMed ID: 38548886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe Inflammatory Reactions in Mice Expressing a GFI1
    Fraszczak J; Arman KM; Lacroix M; Vadnais C; Gaboury L; Möröy T
    J Immunol; 2021 Sep; 207(6):1599-1615. PubMed ID: 34408010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells.
    Fiskus W; Mill CP; Nabet B; Perera D; Birdwell C; Manshouri T; Lara B; Kadia TM; DiNardo C; Takahashi K; Daver N; Bose P; Masarova L; Pemmaraju N; Kornblau S; Borthakur G; Montalban-Bravo G; Manero GG; Sharma S; Stubbs M; Su X; Green MR; Coarfa C; Verstovsek S; Khoury JD; Vakoc CR; Bhalla KN
    Blood Cancer J; 2021 May; 11(5):98. PubMed ID: 34016956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.
    Anastas JN; Zee BM; Kalin JH; Kim M; Guo R; Alexandrescu S; Blanco MA; Giera S; Gillespie SM; Das J; Wu M; Nocco S; Bonal DM; Nguyen QD; Suva ML; Bernstein BE; Alani R; Golub TR; Cole PA; Filbin MG; Shi Y
    Cancer Cell; 2019 Nov; 36(5):528-544.e10. PubMed ID: 31631026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LSD1: biologic roles and therapeutic targeting.
    Maiques-Diaz A; Somervaille TC
    Epigenomics; 2016 Aug; 8(8):1103-16. PubMed ID: 27479862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of JL1037 as a novel, specific, reversible lysine-specific demethylase 1 inhibitor that induce apoptosis and autophagy of AML cells.
    Liu S; Lu W; Li S; Li S; Liu J; Xing Y; Zhang S; Zhou JZ; Xing H; Xu Y; Rao Q; Deng C; Wang M; Wang J
    Oncotarget; 2017 May; 8(19):31901-31914. PubMed ID: 28404874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia.
    Curtiss BM; VanCampen J; Macaraeg J; Kong GL; Taherinasab A; Tsuchiya M; Yashar WM; Tsang YH; Horton W; Coleman DJ; Estabrook J; Lusardi TA; Mills GB; Druker BJ; Maxson JE; Braun TP
    Leukemia; 2022 Jul; 36(7):1781-1793. PubMed ID: 35590033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia.
    Schenk T; Chen WC; Göllner S; Howell L; Jin L; Hebestreit K; Klein HU; Popescu AC; Burnett A; Mills K; Casero RA; Marton L; Woster P; Minden MD; Dugas M; Wang JC; Dick JE; Müller-Tidow C; Petrie K; Zelent A
    Nat Med; 2012 Mar; 18(4):605-11. PubMed ID: 22406747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LSD1 promotes the egress of hematopoietic stem and progenitor cells into the bloodstream during the endothelial-to-hematopoietic transition.
    Tamaoki J; Maeda H; Kobayashi I; Takeuchi M; Ohashi K; Gore A; Bonkhofer F; Patient R; Weinstein BM; Kobayashi M
    Dev Biol; 2023 Sep; 501():92-103. PubMed ID: 37353106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
    Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
    PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML.
    Cusan M; Cai SF; Mohammad HP; Krivtsov A; Chramiec A; Loizou E; Witkin MD; Smitheman KN; Tenen DG; Ye M; Will B; Steidl U; Kruger RG; Levine RL; Rienhoff HY; Koche RP; Armstrong SA
    Blood; 2018 Apr; 131(15):1730-1742. PubMed ID: 29453291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies.
    Tayari MM; Santos HGD; Kwon D; Bradley TJ; Thomassen A; Chen C; Dinh Y; Perez A; Zelent A; Morey L; Cimmino L; Shiekhattar R; Swords RT; Watts JM
    Clin Cancer Res; 2021 Apr; 27(7):1893-1903. PubMed ID: 33495312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1.
    Fiskus W; Mill CP; Birdwell C; Davis JA; Das K; Boettcher S; Kadia TM; DiNardo CD; Takahashi K; Loghavi S; Soth MJ; Heffernan T; McGeehan GM; Ruan X; Su X; Vakoc CR; Daver N; Bhalla KN
    Blood Cancer J; 2023 Apr; 13(1):53. PubMed ID: 37055414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation.
    Liang L; Wang H; Du Y; Luo B; Meng N; Cen M; Huang P; Ganesan A; Wen S
    Bioorg Chem; 2020 Jun; 99():103808. PubMed ID: 32334189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The stem cell factor SALL4 is an essential transcriptional regulator in mixed lineage leukemia-rearranged leukemogenesis.
    Yang L; Liu L; Gao H; Pinnamaneni JP; Sanagasetti D; Singh VP; Wang K; Mathison M; Zhang Q; Chen F; Mo Q; Rosengart T; Yang J
    J Hematol Oncol; 2017 Oct; 10(1):159. PubMed ID: 28974232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CRISPR-suppressor scanning reveals a nonenzymatic role of LSD1 in AML.
    Vinyard ME; Su C; Siegenfeld AP; Waterbury AL; Freedy AM; Gosavi PM; Park Y; Kwan EE; Senzer BD; Doench JG; Bauer DE; Pinello L; Liau BB
    Nat Chem Biol; 2019 May; 15(5):529-539. PubMed ID: 30992567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy.
    Duan Y; Qin W; Suo F; Zhai X; Guan Y; Wang X; Zheng Y; Liu H
    Bioorg Med Chem; 2018 Dec; 26(23-24):6000-6014. PubMed ID: 30448189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML.
    Duy C; Teater M; Garrett-Bakelman FE; Lee TC; Meydan C; Glass JL; Li M; Hellmuth JC; Mohammad HP; Smitheman KN; Shih AH; Abdel-Wahab O; Tallman MS; Guzman ML; Muench D; Grimes HL; Roboz GJ; Kruger RG; Creasy CL; Paietta EM; Levine RL; Carroll M; Melnick AM
    Cancer Discov; 2019 Jul; 9(7):872-889. PubMed ID: 31076479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natural protoberberine alkaloids, identified as potent selective LSD1 inhibitors, induce AML cell differentiation.
    Li ZR; Suo FZ; Guo YJ; Cheng HF; Niu SH; Shen DD; Zhao LJ; Liu ZZ; Maa M; Yu B; Zheng YC; Liu HM
    Bioorg Chem; 2020 Apr; 97():103648. PubMed ID: 32065882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1.
    Carmichael CL; Wang J; Nguyen T; Kolawole O; Benyoucef A; De Mazière C; Milne AR; Samuel S; Gillinder K; Hediyeh-Zadeh S; Vo ANQ; Huang Y; Knezevic K; McInnes WRL; Shields BJ; Mitchell H; Ritchie ME; Lammens T; Lintermans B; Van Vlierberghe P; Wong NC; Haigh K; Thoms JAI; Toulmin E; Curtis DJ; Oxley EP; Dickins RA; Beck D; Perkins A; McCormack MP; Davis MJ; Berx G; Zuber J; Pimanda JE; Kile BT; Goossens S; Haigh JJ
    Blood; 2020 Aug; 136(8):957-973. PubMed ID: 32369597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.